McMillan D D
CMAJ. 1996 Feb 1;154(3):347-9.
The review by Drs. Brousson and Klein (see pages 307 to 315 of this issue) identifies controversies surrounding the administration of vitamin K to babies shortly after birth. Controlled studies comparing the effect of oral and intramuscular administration are unlikely to be conducted because of the large number of subjects needed. The evidence presented in the review should dispel concerns that intramuscular administration may be associated with childhood cancer. Oral administration of a single dose of vitamin K soon after is associated with significant biochemical vitamin K deficiency by 1 month of age, but the relation of biochemical abnormality to clinical manifestations of late hemorrhagic disease of the newborn is less clear. Epidemiologic studies indicate a small, but significant, increase in the incidence rate of hemorrhagic disease after oral administration of vitamin K (1.0 to 6.4 incidents per 1000 000 infants), compared with the incidence rate after intramuscular administration (0.25 incidents per 100 000 infants). Although repeated oral doses of vitamin K may be and effective alternative regimen, there is no approved oral vitamin K formulation, there are concerns about patient compliance, and there has been limited investigation of such regimen. Therefore, intramuscular administration of a single dose of 1.0 mg of vitamin K shortly after birth is recommended.
布鲁松博士和克莱因博士的综述(见本期第307至315页)指出了出生后不久给婴儿服用维生素K所存在的争议。由于所需受试者数量众多,不太可能开展比较口服和肌肉注射效果的对照研究。该综述中所呈现的证据应能消除人们对于肌肉注射可能与儿童癌症有关的担忧。出生后不久口服单剂量维生素K,到1月龄时会出现明显的生化性维生素K缺乏,但生化异常与新生儿晚期出血性疾病临床表现之间的关系尚不清楚。流行病学研究表明,与肌肉注射后的发病率(每10万名婴儿中有0.25例)相比,口服维生素K后出血性疾病的发病率有小幅但显著的上升(每100万名婴儿中有1.0至6.4例)。尽管重复口服维生素K可能是一种有效的替代方案,但目前尚无获批的口服维生素K制剂,存在患者依从性方面的担忧,且对此类方案的研究有限。因此,建议在出生后不久肌肉注射单剂量1.0毫克的维生素K。